73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir

BACKGROUND: Remdesivir (RDV), a RNA polymerase inhibitor with potent in vitro activity against SARS-CoV-2, is the only treatment with demonstrated efficacy in shortening the duration of COVID-19. Here we report regional differences in clinical outcomes of severe COVID-19 patients treated with RDV, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, George, Arribas, Jose Ramon, Robinson, Philip A, Cattelan, Anna Maria, Tashima, Karen T, Tsang, Owen Tak-Yin, Chen, Yao-Shen, SenGupta, Devi, Vendrame, Elena, Blair, Christiana, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Chin, Bum Sik, Spinner, Christoph, Criner, Gerard J, Muñoz, Jose, Lye, David Chien Boon, Gottlieb, Robert L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778124/
http://dx.doi.org/10.1093/ofid/ofaa439.383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778124/
http://dx.doi.org/10.1093/ofid/ofaa439.383

Ejemplares similares